Evidence map›Paper›PMID 32562375›Full record

ArticleJournal of the International AIDS Society2020

Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico.

Javier A Cepeda, Annick Bórquez, Christopher Magana, Anh Vo, Claudia Rafful, Gudelia Rangel, María E Medina-Mora, Steffanie Strathdee, Natasha K Martin

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response.Journal of acquired immune deficiency syndromes (1999) · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Javier A CepedaDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.ORCID 0000-0003-0304-3172
Annick BórquezDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.ORCID 0000-0002-6033-9837
Christopher MaganaDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
Anh VoDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
Claudia RaffulFaculty of Psychology, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico.ORCID 0000-0003-0083-7276
Gudelia RangelComisión de Salud Fronteriza México-Estados Unidos, Tijuana, Mexico.
María E Medina-MoraCenter on Global Mental Health Research, National Institute on Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico.
Steffanie StrathdeeDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
Natasha K MartinDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
University of California System · USEl Colegio de la Frontera Norte · MXInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz · MXSt. Michael's Hospital · CA

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Impact of Drug Policy Reform on the HIV Risk Environment among IDUs in TijuanaR37DA019829 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2010 to 2019
$6.7M
Real-time prediction of emerging drug use epidemics in the United StatesDP2DA049295 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BORQUEZ, ANNICK · 2019 to 2019
$2.4M
Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modelingR01AI147490 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA · 2019 to 2022
$2.3M
MODELING THE IMPACT OF A POLICE EDUCATION PROGRAM ON HIV INCIDENCE AMONG PEOPLE WHO INJECT DRUGSK01DA043421 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CEPEDA, JAVIER · 2017 to 2021
$941k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIAID NIH HHS P30AI036214NIAID NIH HHS R01 AI147490NIAID NIH HHS R01AI147490NIDA NIH HHS DP2 DA049295NIDA NIH HHS DP2DA049295NIDA NIH HHS K01 DA043421NIDA NIH HHS K01DA043421NIDA NIH HHS R37 DA019829NIDA NIH HHS R37DA019829NIH HHS R01AI147490
6 · The paper itself

Abstract

introductionThe HIV epidemic in Tijuana, Mexico is concentrated in key populations, including people who inject drugs (PWID). However, HIV interventions among PWID are minimal, and federal funding was provided for compulsory abstinence programmes associated with HIV and overdose. Alternatively, opioid agonist therapy reduces overdose, reincarceration, HIV, while improving antiretroviral therapy (ART) outcomes. We assessed potential impact and synergies of scaled-up integrated ART and opioid agonist therapy, compared to scale-up of each separately, and potential harms of compulsory abstinence programmes on HIV and fatal overdose among PWID in Tijuana.

methodsWe developed a dynamic model of HIV transmission and overdose among PWID in Tijuana. We simulated scale-up of opioid agonist therapy from zero to 40% coverage among PWID. We evaluated synergistic benefits of an integrated harm reduction and ART scale-up strategy (40% opioid agonist therapy coverage and 10-fold ART recruitment), compared to scale-up of each intervention alone or no scale-up of low coverage ART and no harm reduction). We additionally simulated compulsory abstinence programmes (associated with 14% higher risk of receptive syringe sharing and 76% higher odds of overdose) among PWID.

resultsWithout intervention, HIV incidence among PWID could increase from 0.72 per 100 person-years (PY) in 2020 to 0.92 per 100 PY in 2030. Over ten years, opioid agonist therapy scale-up could avert 31% (95% uncertainty interval (UI): 18%, 46%) and 22% (95% UI: 10%, 28%) new HIV infections and fatal overdoses, respectively, with the majority of HIV impact from the direct effect on HIV transmission due to low ART coverage. Integrating opioid agonist therapy and ART scale-up provided synergistic benefits, with opioid agonist therapy effects on ART recruitment/retention averting 9% more new infections compared to ART scale-up alone. The intervention strategy could avert 48% (95% UI: 26%, 68%) of new HIV infections and one-fifth of fatal overdoses over ten years. Conversely, compulsory abstinence programmes could increase HIV and overdoses.

conclusionsIntegrating ART with opioid agonist therapy could provide synergistic benefits and prevent HIV and overdoses among PWID in Tijuana, whereas compulsory abstinence programmes could cause harm. Policymakers should consider the benefits of integrating harm reduction and HIV services for PWID.

Indexed as

Harm ReductionAnalgesics, OpioidAnti-HIV AgentsDrug OverdoseEpidemicsFemaleHIV InfectionsHumansIncidenceMaleMexicoModels, BiologicalNeedle SharingSubstance Abuse, IntravenousAnalgesics, OpioidAnti-HIV Agentsdrug treatmentHIVinject drugsintegrationMexicoopioid agonist therapyoverdose

Identifiers

PMID32562375
PMCPMC7305416
OpenAlexW3036470201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.